Opko deal flurry continues with $480m Prolor buy
This article was originally published in Scrip
Executive Summary
Opko Health's flurry of M&A activity continues with news that it has agreed to buy Prolor, an Israeli-headquartered biopharmaceutical company focused on developing and commercializing longer-acting versions of already approved therapeutic proteins, in an all-stock transaction valued at $480 million.